Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001576187 | SCV001803321 | likely benign | not provided | 2021-03-17 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge |
Ce |
RCV001576187 | SCV002062664 | likely benign | not provided | 2024-03-01 | criteria provided, single submitter | clinical testing | TNXB: BP4 |
Genome Diagnostics Laboratory, |
RCV002276671 | SCV002566280 | uncertain significance | Ehlers-Danlos syndrome | 2022-03-15 | criteria provided, single submitter | clinical testing | |
MGZ Medical Genetics Center | RCV002290670 | SCV002579867 | uncertain significance | Ehlers-Danlos syndrome due to tenascin-X deficiency | 2021-12-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002348856 | SCV002651237 | likely benign | Cardiovascular phenotype | 2024-10-03 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Mayo Clinic Laboratories, |
RCV001576187 | SCV005412104 | uncertain significance | not provided | 2024-07-29 | criteria provided, single submitter | clinical testing | BP4 |
Prevention |
RCV003945953 | SCV004766216 | likely benign | TNXB-related disorder | 2023-04-05 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |